188 related articles for article (PubMed ID: 32726783)
1. JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.
Rojas P; Sarmiento M
Acta Haematol; 2021; 144(3):314-318. PubMed ID: 32726783
[TBL] [Abstract][Full Text] [Related]
2. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Goker Bagca B; Biray Avci C
Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
[TBL] [Abstract][Full Text] [Related]
3. Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.
Mortara A; Mazzetti S; Margonato D; Delfino P; Bersano C; Catagnano F; Lauriola M; Grosso P; Perseghin G; Ippoliti G
Clin Transl Sci; 2021 May; 14(3):1062-1068. PubMed ID: 33403775
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids.
Sarmiento M; Rojas P; Jerez J; Bertín P; Campbell J; García MJ; Pereira J; Triantafilo N; Ocqueteau M
Acta Haematol; 2021; 144(6):620-626. PubMed ID: 34111867
[TBL] [Abstract][Full Text] [Related]
5. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
Chen CX; Wang JJ; Li H; Yuan LT; Gale RP; Liang Y
Leukemia; 2021 Sep; 35(9):2616-2620. PubMed ID: 33990684
[TBL] [Abstract][Full Text] [Related]
6. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation.
Meyer LK; Verbist KC; Albeituni S; Scull BP; Bassett RC; Stroh AN; Tillman H; Allen CE; Hermiston ML; Nichols KE
Blood; 2020 Aug; 136(6):657-668. PubMed ID: 32530039
[TBL] [Abstract][Full Text] [Related]
7. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.
Vannucchi AM; Sordi B; Morettini A; Nozzoli C; Poggesi L; Pieralli F; Bartoloni A; Atanasio A; Miselli F; Paoli C; Loscocco GG; Fanelli A; Para O; Berni A; Tassinari I; Zammarchi L; Maggi L; Mazzoni A; Scotti V; Falchetti G; Malandrino D; Luise F; Millotti G; Bencini S; Capone M; Piccinni MP; Annunziato F; Guglielmelli P;
Leukemia; 2021 Apr; 35(4):1121-1133. PubMed ID: 32814839
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
Cao Y; Wei J; Zou L; Jiang T; Wang G; Chen L; Huang L; Meng F; Huang L; Wang N; Zhou X; Luo H; Mao Z; Chen X; Xie J; Liu J; Cheng H; Zhao J; Huang G; Wang W; Zhou J
J Allergy Clin Immunol; 2020 Jul; 146(1):137-146.e3. PubMed ID: 32470486
[TBL] [Abstract][Full Text] [Related]
9. The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Neubauer A; Johow J; Mack E; Burchert A; Meyn D; Kadlubiec A; Torje I; Wulf H; Vogelmeier CF; Hoyer J; Skevaki C; Muellenbach RM; Keller C; Schade-Brittinger C; Rolfes C; Wiesmann T
Leukemia; 2021 Oct; 35(10):2917-2923. PubMed ID: 34385593
[TBL] [Abstract][Full Text] [Related]
10. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
Koschmieder S; Jost E; Cornelissen C; Müller T; Schulze-Hagen M; Bickenbach J; Marx G; Kleines M; Marx N; Brümmendorf TH; Dreher M
Eur J Haematol; 2020 Nov; 105(5):655-658. PubMed ID: 32593209
[TBL] [Abstract][Full Text] [Related]
11. Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats.
Calbet M; Ramis I; Calama E; Carreño C; Paris S; Maldonado M; Orellana A; Calaf E; Pauta M; De Alba J; Bach J; Miralpeix M
J Pharmacol Exp Ther; 2019 Aug; 370(2):137-147. PubMed ID: 31085698
[TBL] [Abstract][Full Text] [Related]
12. Clinically used JAK inhibitor blunts dsRNA-induced inflammation and calcification in aortic valve interstitial cells.
Parra-Izquierdo I; Sánchez-Bayuela T; Castaños-Mollor I; López J; Gómez C; San Román JA; Sánchez Crespo M; García-Rodríguez C
FEBS J; 2021 Nov; 288(22):6528-6542. PubMed ID: 34009721
[TBL] [Abstract][Full Text] [Related]
13. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
Front Immunol; 2020; 11():620098. PubMed ID: 33658996
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
[TBL] [Abstract][Full Text] [Related]
15. Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
Fetter T; Rios GC; Niebel D; Bieber T; Wenzel J
Acta Derm Venereol; 2020 May; 100(10):adv00144. PubMed ID: 32285135
[TBL] [Abstract][Full Text] [Related]
16. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
La Rosée F; Bremer HC; Gehrke I; Kehr A; Hochhaus A; Birndt S; Fellhauer M; Henkes M; Kumle B; Russo SG; La Rosée P
Leukemia; 2020 Jul; 34(7):1805-1815. PubMed ID: 32518419
[TBL] [Abstract][Full Text] [Related]
17. JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids.
Nystrom SE; Li G; Datta S; Soldano KL; Silas D; Weins A; Hall G; Thomas DB; Olabisi OA
JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35472001
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
Chen CY; Chen WC; Hsu CK; Chao CM; Lai CC
Int Immunopharmacol; 2021 Oct; 99():108027. PubMed ID: 34343937
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 in a pediatric patient with Glanzmann thrombasthenia.
Sattler L; Feugeas O; Hager C; Grunebaum L; Desprez D
Pediatr Blood Cancer; 2020 Oct; 67(10):e28662. PubMed ID: 32798297
[No Abstract] [Full Text] [Related]
20. Current and future status of JAK inhibitors.
McLornan DP; Pope JE; Gotlib J; Harrison CN
Lancet; 2021 Aug; 398(10302):803-816. PubMed ID: 34454676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]